| Bioactivity | AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects[1]. | ||||||||||||
| Target | IC50: 1.2 nM (FAAH/MAGL) | ||||||||||||
| Name | FAAH/MAGL-IN-5 | ||||||||||||
| CAS | 1010096-65-7 | ||||||||||||
| Formula | C17H17N5O | ||||||||||||
| Molar Mass | 307.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Vinogran Naidoo, et al.Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.Neurotherapeutics.2012 Oct;9(4):801-13. |